Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co.

Burney Co. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 78.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,352 shares of the company's stock after selling 99,173 shares during the quarter. Burney Co.'s holdings in Neurocrine Biosciences were worth $3,734,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock worth $593,186,000 after purchasing an additional 539,936 shares in the last quarter. 1832 Asset Management L.P. raised its holdings in shares of Neurocrine Biosciences by 1,370.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company's stock valued at $74,507,000 after buying an additional 504,400 shares during the period. Los Angeles Capital Management LLC lifted its position in Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock worth $48,479,000 after acquiring an additional 363,863 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock worth $166,959,000 after acquiring an additional 228,444 shares during the period. Finally, Braidwell LP grew its position in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company's stock valued at $105,734,000 after acquiring an additional 158,665 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the company's stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jude Onyia sold 2,331 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,694 shares of company stock worth $479,230 in the last three months. 4.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NBIX. UBS Group boosted their target price on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Raymond James reissued an "outperform" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Royal Bank of Canada reduced their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a report on Friday, October 4th. Finally, StockNews.com downgraded Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $164.81.

Neurocrine Biosciences Trading Up 2.2 %

Shares of Neurocrine Biosciences stock opened at $142.56 on Thursday. The stock has a market capitalization of $14.43 billion, a price-to-earnings ratio of 38.22 and a beta of 0.33. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The business's 50 day simple moving average is $131.13 and its 200-day simple moving average is $131.11.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.